Astec LifeSciences Limited — Updates, 28-07-2025: Press Release

Astec LifeSciences' Board has approved the financial results for the quarter. The company saw consolidated total income rise 30.3% to Rs. 91.6 Cr (Q1FY26 vs Q1FY25). Critically, EBITDA loss narrowed significantly to Rs. 10.5 Cr from Rs. 45.3 Cr. This operational turnaround was fueled by robust growth: Enterprise revenue climbed 68.2% and Contract Manufacturing (CDMO) surged 85.7%. Improved volumes and reduced prior-year inventory write-down impact bolstered profitability, with exports up 48.1%.